List view / Grid view
Kisqali plus letrozole achieved a median overall survival (OS) of over five years (63.9 months), with OS benefit increasing over time, according to newly published data.
Kisqali plus letrozole achieved a median overall survival of over five years, the longest ever reported for HR+/HER2 breast cancer.
A new study suggests breast cancer patients taking palbociclib/letrozole combination therapy should avoid foods rich in xenoestrogens...
NICE recommends Kisqali as a cost-effective treatment option for postmenopausal women within England and Wales with advanced breast cancer...
According to results of the LORELEI clinical trial, adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer...
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
Researchers have connected docosahexaenoic (DHA) synthesis to oestrogen production and consequentially brain health...
